An observational study in Hypohidrotic Ectodermal Dysplasia, sponsored by University Hospital Erlangen. Completed at 1 site in Germany. Per ClinicalTrials.gov, last updated 2021-08-16.
Sponsored by University Hospital Erlangen · Observational
Longitudinal study of 56 households with at least one member who had COVID-19 to compare the course of illness, immune responses, and long-term consequences of SARS-CoV-2 infection in HED patients with those of control subjects of the same age group. Complete households are investigated, including women who are pregnant when exposed to the virus and their newborn child(ren).
households with children and/or adolescents and at least one member who has or had a SARS-CoV-2 infection
Exclusion Criteria:
all household members with hypohidrotic ectodermal dysplasia (HED), a rare hereditary developmental disorder
individuals of the same age group, but without HED, including pregnant women
age-dependence of SARS-CoV-2 infection
registry of household members with and without symptoms of COVID-19 (entire households)
Time frame: 3 months from the point in time at which the first household member shows symptoms of COVID-19
percentage of household members infected by SARS-CoV-2
The infection rate is determined on the basis of specific PCR tests and detectibility of antibodies against SARS-CoV-2.
Time frame: 3 months from the point in time at which the first household member shows symptoms of COVID-19
duration of primary COVID-19 symptoms
The possible association between the length of time with symptoms of COVID-19 and specific immune responses, in particular the development of virus-neutralizing antibodies, is studied.
Time frame: 2 months from the onset of COVID-19 symptoms
frequency of late-onset cardiovascular complications
Patient-reported known and yet unknown long-term consequences of COVID-19 are registered and investigated further (questionnaire, specific data confirmed by clinical examination).
Time frame: 2-12 months from the onset of COVID-19 symptoms
frequency of postviral fatigue
Patient-reported symptoms of fatigue are registered (questionnaire).
Time frame: 2-12 months from the onset of COVID-19 symptoms
frequency of noticeable temporary hair loss after COVID-19
Patient-reported extent of hair loss is registered (questionnaire).
Time frame: 2-12 months from the onset of COVID-19 symptoms
This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital Erlangen